Date: 2015-03-19
Type of information: Licensing agreement
Compound: HM71224
Company: Eli Lilly (USA - IN) Hanmi Pharmaceutical (South Korea)
Therapeutic area: Autoimmune diseases
Type agreement: licensing collaboration
Action mechanism: kinase inhibitor/Bruton\'s tyrosine kinase inhibitor. HM71224 is an oral Bruton\'s tyrosine kinase (BTK) inhibitor. Hanmi Pharmaceutical has presented interim clinical data results of HM71224, in EULAR 2014 Paris from June 11th through 14th. Date of a phase 1 study targeting 58 healthy volunteers in Netherlands indicated that a proportional absorption of HM71224 in body to increasing dose was observed in healthy volunteers from both single dose and multiple doses. It also indicated that the results were not affected by food intake.
Disease:
Details: * On March 19, 2015, Eli Lilly and Hanmi Pharmaceutical announced they have entered into an exclusive license and collaboration agreement for the development and commercialization of Hanmi\'s oral Bruton\'s tyrosine kinase (BTK) inhibitor, HM71224, for the treatment of autoimmune and other diseases. This small molecule is ready to enter Phase II and the parties plan to investigate the molecule for the potential treatment of rheumatoid arthritis, lupus, lupus nephritis, Sjögren\'s syndrome, and other related conditions. Under the terms of the agreement, Lilly will receive worldwide rights to the molecule for all indications excluding China, Hong Kong, Taiwan, and Korea. Lilly will take development, regulatory, manufacturing, and commercial leadership for the molecule in the Lilly territories.
Financial terms: Hanmi will receive an initial payment of $50 million and is eligible for up to $640 million in potential development, regulatory, and sales milestones. If the BTK inhibitor is successfully commercialized, Hanmi would also be eligible for tiered double-digit royalty payments.
Latest news:
